Agios Pharmaceuticals, Inc. (AGIO)
Develops medicines that fix broken enzymes causing rare blood disorders.
$35.99-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+2.8%
The outlook
Analysts broadly support AGIO with a Buy consensus, and the average price target sits roughly 19% above the current price. The stock is trading above both its 50- and 200-day moving averages, signaling upward momentum in the near term. Currently positioned about midway through its 52-week range, the data reflects a constructive technical backdrop.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range58% of the way from its 52-week low to high
Price targetAvg target +19% vs current price
Analyst price target
~12-month · 8 analysts$42.75average target+18.8% vs now
Now $35.99
Low $31.00High $62.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.14B
52-wk high
$46.00
52-wk low
$22.24
50-day avg
$33.77
200-day avg
$31.79
Trailing P/E
—